
About Spherix Global Insights

Spherix is the world's leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.



Spherix Provides Independent Expertise in Eleven Areas

- Dermatology
- Nephrology
- Gastroenterology
- Neuroscience
- Rheumatology
- Ophthalmology
- Hematology
- Oncology

NEW IN 2026!

- Obesity
- Respiratory
- Market Access

This is a guide to the publications Spherix will produce in 2026. It is organized by therapeutic area, indication, and deliverable.

Type of Publications

MARKET DYNAMIX	*A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.*
REALTIME DYNAMIX	*A US quarterly or EU4 +UK semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.*
LAUNCH DYNAMIX	*Published monthly, Launch Dynamix tracks a new brand's first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.*
PATIENT CHART DYNAMIX	*A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmasks real patient management patterns an uncovers the "why" behind treatment decisions.*
PATIENT VOICE DYNAMIX	*An independent service that explores the voice of the patient as they progress through their disease and treatment journeys.*
ACCOUNT MANAGEMENT DYNAMIX	*Identify best practices to build high-performing national and regional account teams and benchmark your performance against competitors.*
BENEFIT DESIGN DYNAMIX	*Understand and predict market access trends and policy shifts affecting formulary management and reimbursement across commercial and government channels.*
KEY ACCOUNT DYNAMIX	*Gain strategic account intelligence on leading national and regional payers, IDNs, and specialty pharmacy accounts to support prioritization, engagement strategy, and planning.*
PATIENT SERVICES DYNAMIX	*Uncover best practices and comparative intelligence on indication and brand-level patient service programs and competencies.*
SPECIAL TOPIX	*Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.*
RAPIDPULSE DYNAMIX	*Address focused, time-sensitive business questions using direct input from physicians, payers, and other healthcare decision-makers. Each engagement combines tailored methodology, therapeutic and market expertise, and AI-enabled execution.*

For a complete index of available reports, visit
www.clientportal.spherixglobalinsights.com

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

2026 & 2027 Market Access Publications

SPHERIX GLOBAL INSIGHTS

BENEFIT DESIGN DYNAMIX

Introduction	• *Market & Stakeholder Landscape*
Commercial Trends	• *Pharmacy Benefits* • *Medical Benefits* • *Employer Trends & Influence*
Government Trends	• *Medicare Part D Benefits* • *Medicare Part B Benefits* • *Medicaid, Exchanges, & Other Government Programs*

KEY ACCOUNT DYNAMIX

Comparative Assessments	• *Leading Accounts* • *Blues & Regional Plans* • *Integrated Delivery Networks* • *Specialty Pharmacies*
Account Profiles	• Leading Accounts (19 profiles) • Blues & Regional Plans (40 profiles) • Integrated Delivery Networks (50 profiles) • Specialty Pharmacies (16 profiles)

ACCOUNT MANAGEMENT DYNAMIX

Payer Benchmarking	• *Medical Directors* • *Pharmacy Directors* • *Annual Review*
IDN Benchmarking	• *Medical Directors* • *Pharmacy Directors* • *Annual Review*
Benchmarking by Specialty	• ***Oncology*** [+] • ***Urology*** [+]

PATIENT SERVICES DYNAMIX

Autoimmune Market	• *Patient Services Program Benchmarking* • *Patient Services Best Practices*
Oncology Market	• *Patient Services Program Benchmarking* • *Patient Services Best Practices*
Orphan/Rare Market	• *Patient Services Program Benchmarking* • *Patient Services Best Practices*
Women's Health Market	• *Patient Services Program Benchmarking* • *Patient Services Best Practices*

SPECIAL TOPIX

- Pathways Influence in Oncology Access- Overall and by Tumor Type
- ***Government Pricing in Transition: MFP and MFN Dynamics*** [+]
- ***Direct-to-Patient Access: New Pharmaceutical Channel Impact on Access*** [+]
- ***AI-Enabled Market Access: Payer Decisions and Evidence Strategies*** [+]
- ***PBM Market Evolution: Reform, Alternative Model, and Buyer Expectations*** [+]

Key

BENEFIT DESIGN DYNAMIX	Explore commercial and government payer, physician and employer market experiences
KEY ACCOUNT DYNAMIX	*Reports use detailed data from key decision-makers from leading national payers, regional payers, IDNs and specialty pharmacies.*
ACCOUNT MANAGEMENT DYNAMIX	*Reports use extensive data from medical directors and pharmacy directors at payers and IDNs.*
PATIENT SERVICES DYNAMIX	*Assesses physician, office staff, patient and caregiver experiences with patient service programs and attributes*
SPECIAL TOPIX	*Current events on specific interest areas Current events*
RAPIDPULSE DYNAMIX	*Rapid market intelligence for time-sensitive decisions*

*Pending approvals and launch

[+] ***New in 2027***

Publications may change due to factors such as FDA approval status and other market events

2026 & 2027 Dermatology Publications

SPHERIX GLOBAL INSIGHTS

Alopecia Areata

MARKET DYNAMIX	• *Alopecia Areata, US*
LAUNCH DYNAMIX	• *Leqselvi (SUN Pharma) in Alopecia Areata, US* • ***Rinvoq (AbbVie) in Alopecia Areata, US*+***

Atopic Dermatitis

MARKET DYNAMIX	• *Atopic Dermatitis, JP*
REALTIME DYNAMIX	• *Atopic Dermatitis, US* • *Atopic Dermatitis, EU4 +UK*
LAUNCH DYNAMIX	• *Ebglyss (Eli Lilly) in Atopic Dermatitis, US* • *Nemluvio (Galderma) in Atopic Dermatitis, US* • *Vtama and Zoryve (Organon/ Arcutis) in Atopic Dermatitis, US*
PATIENT CHART DYNAMIX	• *Atopic Dermatitis, US*
PATIENT VOICE DYNAMIX	• *Atopic Dermatitis, US* • *Atopic Dermatitis, EU4 +UK*

Chronic Spontaneous Urticaria

MARKET DYNAMIX	• *Chronic Spontaneous Urticaria, US*
LAUNCH DYNAMIX	• ***Barzolvolimab (Celldex) in CSU, US*+*** • *Dupixent (Sanofi/Regeneron) in CSU, US* • *Rhapsido (Novartis) in CSU, US*
PATIENT CHART DYNAMIX	• *Chronic Spontaneous Urticaria, US*

Prurigo Nodularis

MARKET DYNAMIX	• Prurigo Nodularis, US
LAUNCH DYNAMIX	• *Nemluvio (Galderma) in Prurigo Nodularis, US* • ***Povorcitinib (Incyte) in Prurigo Nodularis, US*+***

Plaque Psoriasis

REALTIME DYNAMIX	• *Plaque Psoriasis, US* • *Plaque Psoriasis, EU4 +UK*
LAUNCH DYNAMIX	• *Icotyde (J&J) in Plaque Psoriasis, US*
PATIENT VOICE DYNAMIX	• *Plaque Psoriasis, US*
SPECIAL TOPIX	• *The Oral Opportunity in Plaque Psoriasis, US*

Hidradenitis Suppurativa

MARKET DYNAMIX	• *Hidradenitis Suppurativa, US*
LAUNCH DYNAMIX	• *Bimzelx (UCB) in Hidradenitis Suppurativa, US* • ***Povorcitinib (Incyte) in Hidradenitis Suppurativa, US*+*** • ***Sonelokimab (MoonLake) in Hidradenitis Suppurativa, US*+*** • ***Rinvoq (AbbVie) in Hidradenitis Suppurativa, US*+***

Other Dermatology Indications

MARKET DYNAMIX	• *Vitiligo, US*
LAUNCH DYNAMIX	• ***Povorcitinib (Incyte) in Vitiligo, US*+*** • ***Rinvoq (AbbVie) in Vitiligo, US*+***
SPECIAL TOPIX	• *Biologic Coordinators Across Dermatology, US* • ***Dermatologist Use of AI+*** • ***Dermatology Patient Use of AI+***

Dermatology-Adjacent Indications

MARKET DYNAMIX	• *Asthma, US* • *Asthma, EU* • *Chronic Obstructive Pulmonary Disease, US* • *Chronic Obstructive Pulmonary Disease, EU*
PATIENT VOICE DYNAMIX	• ***Asthma, US+*** • ***Chronic Obstructive Pulmonary Disease, US+***

Key

MARKET DYNAMIX	*Yearly market overview of key indication*
REALTIME DYNAMIX	*Quarterly (US) or semi-annual (EU4 +UK) indication updates*
LAUNCH DYNAMIX	*Monthly benchmark of newly launched products*
PATIENT CHART DYNAMIX	*Yearly review of large-scale patient chart audits*
PATIENT VOICE DYNAMIX	*Independent service capturing patient journey insights*
SPECIAL TOPIX	*Current events on specific interest areas*
RAPIDPULSE DYNAMIX	*Rapid market intelligence for time-sensitive decisions*

**Pending approvals and launch*

+ New in 2027

Publications may change due to factors such as FDA approval status and other market events

2026 & 2027 Gastroenterology Publications

Inflammatory Bowel Disease

MARKET DYNAMIX	• *Crohn's Disease, EU4 +UK (refresh)* • *Crohn's Disease, JP* • *Ulcerative Colitis, EU4 +UK (refresh)* • *Ulcerative Colitis, JP*
REALTIME DYNAMIX	• *Crohn's Disease, US* • *Ulcerative Colitis, US*
LAUNCH DYNAMIX	• *Tremfya (Janssen) in Crohn's Disease, US* • ***Obefazimod (Abivax) in Ulcerative Colitis, US*⁺*** • *Omvoh (Eli Lilly) in Crohn's Disease, US* • *Tremfya (Janssen) in Ulcerative Colitis, US*
PATIENT CHART DYNAMIX	• *Inflammatory Bowel Disease New Starts, US* • *Inflammatory Bowel Disease Switching, US* • *Inflammatory Bowel Disease Switching, EU4 +UK*
PATIENT VOICE DYNAMIX	• *Inflammatory Bowel Disease, US*
SPECIAL TOPIX	• *Biologic Coordinators in Gastroenterology, US* • *The Role of APPs in IBD*

Obesity

MARKET DYNAMIX	• *Obesity, US*
LAUNCH DYNAMIX	• *Wegovy Pill (Novo Nordisk) in Obesity, US* • *Foundayo (Eli Lilly) in Obesity, US* • *CagriSema (Novo Nordisk) in Obesity, US** • ***Retatrutide (Eli Lilly) in Obesity, US*⁺***
PATIENT CHART DYNAMIX	• ***Obesity, US⁺***
PATIENT VOICE DYNAMIX	• ***Obesity, US⁺***

MASH

MARKET DYNAMIX	• *MASH, US* • *MASH, EU4 +UK*
LAUNCH DYNAMIX	• *Rezdiffra (Madrigal) in MASH, US* • *Wegovy (Novo Nordisk) in MASH, US*
PATIENT CHART DYNAMIX	• *MASH, US*
PATIENT VOICE DYNAMIX	• ***MASH, US⁺***
SPECIAL TOPIX	• *MASH Screening and Management among PCPs and Endocrinologists, US*

Other Gastroenterology Indications

MARKET DYNAMIX	• ***Autoimmune Hepatitis (AIH), US⁺*** • *Celiac Disease, US (refresh)* • ***Chronic Hepatitis D Virus, US⁺*** • *Eosinophilic Esophagitis , US* • *Primary Biliary Cholangitis/ Primary Sclerosing Cholangitis, US (2025)*
LAUNCH DYNAMIX	• *Iqirvo (Ipsen) in Primary Biliary Cholangitis, US* • *Linavoy (Alfasigma) in Cholestatic Pruritus Among PBC Patients, US* • *Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US* • ***Lynavoy (GSK) in Cholestatic Pruritus Associated with Primary Biliary Cholangitis, US*⁺*** • ***Saroglitazar (Zydus) in Primary Biliary Cholangitis, US*⁺***
SPECIAL TOPIX	• ***Gastroenterologist Use of AI⁺*** • ***Gastroenterology Patient Use of AI⁺*** • ***Primary Care Physician Use of AI⁺***

Key

MARKET DYNAMIX	*Yearly market overview of key indication*
REALTIME DYNAMIX	*Quarterly (US) or semi-annual (EU4 +UK) indication updates*
LAUNCH DYNAMIX	*Monthly benchmark of newly launched products*
PATIENT CHART DYNAMIX	*Yearly review of large-scale patient chart audits*
PATIENT VOICE DYNAMIX	*Independent service capturing patient journey insights*
SPECIAL TOPIX	*Current events on specific interest areas*
RAPIDPULSE DYNAMIX	*Rapid market intelligence for time-sensitive decisions*

*Pending approvals and launch

⁺ ***New in 2027***

Publications may change due to factors such as FDA approval status and other market events

2026 & 2027 Hematology Publications

Bleeding Disorders

MARKET DYNAMIX	• *Hemophilia A & B, US* • *Hemophilia A & B, EU4 +UK* • *Von Willebrand Disease, US*
LAUNCH DYNAMIX	• *Qfitlia (Sanofi) in Hemophilia A & B, US* • *Mim8 (Novo Nordisk) in Hemophilia A, US**
PATIENT CHART DYNAMIX	• *People with Bleeding Disorders*
PATIENT VOICE DYNAMIX	• *People with Bleeding Disorders*
SPECIAL TOPIX	• *Women, Girls, and people who have or have had the potential to menstruate (WGPPM) with Bleeding Disorders*

Hemoglobinopathies

MARKET DYNAMIX	• *Sickle Cell Disease, US* • *Thalassemia, US*
LAUNCH DYNAMIX	• *Aqvesme (Agios Pharmaceuticals) in Thalassemia, US* • ***Aqvesme in SCD, US*** [+]
PATIENT CHART DYNAMIX	• *Sickle Cell Disease, US* • *Thalassemia, US*
PATIENT VOICE DYNAMIX	• *Sickle Cell Disease, US*
SPECIAL TOPIX	• ***Primary Care in Sickle Cell Disease, US*** [+]

Paroxysmal Nocturnal Hemoglobinuria

MARKET DYNAMIX	• *Paroxysmal Nocturnal Hemoglobinuria, US*

Other Benign Hematology Indications

MARKET DYNAMIX	• *Warm Autoimmune Hemolytic Anemia (w-AIHA), US* • *Immune Thrombocytopenic Purpura (ITP), US*
LAUNCH DYNAMIX	• *Nipocalimab (J&J) in w-AIHA, US** • *Wayrilz (Sanofi) in ITP, US*
PATIENT CHART DYNAMIX	• ***Immune Thrombocytopenic Purpura (ITP), US*** [+]

Other Hematology Indications

SPECIAL TOPIX	• *AI in Hematology and Oncology, US (2026)* • ***Gene Therapy, US*** [+] • ***Hematologist Use of AI*** [+]

Key

MARKET DYNAMIX	*Yearly market overview of key indication*
REALTIME DYNAMIX	*Quarterly (US) or semi-annual (EU4 +UK) indication updates*
LAUNCH DYNAMIX	*Monthly benchmark of newly launched products*
PATIENT CHART DYNAMIX	*Yearly review of large-scale patient chart audits*
PATIENT VOICE DYNAMIX	*Independent service capturing patient journey insights*
SPECIAL TOPIX	*Current events on specific interest areas*
RAPIDPULSE DYNAMIX	*Rapid market intelligence for time-sensitive decisions*

**Pending approvals and launch*

[+] ***New in 2027***

Publications may change due to factors such as FDA approval status and other market events

2026 & 2027 Nephrology Publications

SPHERIX GLOBAL INSIGHTS

Glomerular Disease

MARKET DYNAMIX	• *Alport Syndrome, US* • *FSGS, US* • *Membranous Nephropathy, US* • ***APOL-1 Mediated Kidney Disease, US +*** • ***IgAN, Brazil +*** • ***IgAN, Canada +*** • ***IgAN, China +*** • ***IgAN, Japan +*** • ***IgAN, KSA +*** • ***IgAN, UAE +***
REALTIME DYNAMIX	• *IgAN, US* • IgAN, EU4+UK
LAUNCH DYNAMIX	• *Filspari (Travere) in FSGS, US* • *Voyxact (Otsuka) in IgAN, US* • *Trutakna (Vera) in IgAN, US* • ***Povetacicept (Vertex) in IgAN, US * +*** • ***Ultomiris (Alexion) in IgAN, US * +*** • ***Gazyva (Genentech) in pMN, US * +***
PATIENT CHART DYNAMIX	• *FSGS, US* • *IgAN, US* • *IgAN, China* • *IgAN, EU4+UK* • *IgAN, Japan* • ***IgAN, Brazil +*** • ***APOL-1Mediated Kidney Disease, US +*** • ***Membranous Nephropathy, US +***
PATIENT VOICE DYNAMIX	• *IgAN, US* • ***FSGS, US +***
SPECIAL TOPIX	• *ASN Feedback: Focus on Glomerular Disease*

CKD, Dialysis & Transplant

MARKET DYNAMIX	• ***Transplant/AMR, US +*** • ***AD-PKD, US +*** • ***CKM, US +*** • ***Dialysis, US (covers Devices and Machines, HP, and SHPT) +***
REALTIME DYNAMIX	• *Dialysis, US (Nephrologist; Renal Dietitians)*
LAUNCH DYNAMIX	• ***OLC (Unicycive) in Hyperphosphatemia, US * +***
PATIENT CHART DYNAMIX	• ***Transplant/AMR, US +*** • *Chronic Kidney Disease, Non-Dialysis, Nephrologist, US* • *Chronic Kidney Disease, Non-Dialysis, PCP, US* • *Dialysis, US*
PATIENT VOICE DYNAMIX	• *Chronic Kidney Disease, US*
SPECIAL TOPIX	• ***Biologic Coordinators & Access Facilitators in Nephrology +*** • ***Decision-Making in AI (Nephrologists, PCPs) +*** • ***Nephrology Pipeline, US +*** • ***Nephrologist Use of AI +*** • ***Primary Care Physician Use of AI +***

Key

MARKET DYNAMIX	*Yearly market overview of key indication*
REALTIME DYNAMIX	*Quarterly (US) or semi-annual (EU4 +UK) indication updates*
LAUNCH DYNAMIX	*Monthly benchmark of newly launched products*
PATIENT CHART DYNAMIX	*Yearly review of large-scale patient chart audits*
PATIENT VOICE DYNAMIX	*Independent service capturing patient journey insights*
SPECIAL TOPIX	*Current events on specific interest areas*
RAPIDPULSE DYNAMIX	*Rapid market intelligence for time-sensitive decisions*

*Pending approvals and launch

+ ***New in 2027***

Publications may change due to factors such as FDA approval status and other market events

2026 & 2027 Neuroscience Publications

Alzheimer's Disease

MARKET DYNAMIX	• *Alzheimer's Disease, US*
PATIENT CHART DYNAMIX	• *Alzheimer's Disease, US*

Migraine

MARKET DYNAMIX	• ***Menstrual Migraine, US +***
LAUNCH DYNAMIX	• ***Dysport (Ipsen) in Migraine, US* +***
REALTIME DYNAMIX	• *Migraine (Neurologists & PCPs), US* • ***Migraine, EU4 + UK +***
PATIENT CHART DYNAMIX	• ***Migraine, US +*** • ***Migraine, EU4 + UK +***
PATIENT VOICE DYNAMIX	• ***Migraine, US +***

Multiple Sclerosis

MARKET DYNAMIX	• *Multiple Sclerosis, US*
LAUNCH DYNAMIX	• ***Fenebrutinib (Genentech) in Multiple Sclerosis, US* +*** • ***Remibrutinib (Novartis) in Multiple Sclerosis, US* +***
PATIENT CHART DYNAMIX	• *Multiple Sclerosis, US*
SPECIAL TOPIX	• *Post-ACTRIMS/ECTRIMS Coverage* • ***Biologic Coordinators in Multiple Sclerosis, US +***

Other Neuroscience Indications

MARKET DYNAMIX	• *Chronic Inflammatory Demyelinating Polyneuropathy, US* • ***Parkinson's Disease, US +*** • ***Narcolepsy/Sleep Disorders, US +*** • ***Rett Syndrome, US +*** • ***Rare Neuro-Immune Indications, US +***
LAUNCH DYNAMIX	• ***Tavapadon (AbbVie) in Parkinson's Disease, US* +***
SPECIAL TOPIX	• *Cell Therapies in Neuro-Immune Indications* • ***Neurologist Use of AI +*** • ***Primary Care Physician Use of AI +***

Generalized Myasthenia Gravis

REALTIME DYNAMIX	• *Generalized Myasthenia Gravis, US* • *Generalized Myasthenia Gravis, EU4 +UK*
LAUNCH DYNAMIX	• *Uplizna, (Amgen) in Generalized Myasthenia Gravis, US* • *Imaavy, (J&J) in Generalized Myasthenia Gravis, US* • ***Cemdisiran, (Regeneron) in Generalized Myasthenia Gravis, US* +*** • ***Gefurulimab, (Alexion/AZ) in Generalized Myasthenia Gravis, US* +*** • ***Descartes-08 (Cartesian) in Generalized Myasthenia Gravis, US* +***
PATIENT CHART DYNAMIX	• *Generalized Myasthenia Gravis, US* • *Generalized Myasthenia Gravis, EU4 +UK*
PATIENT VOICE DYNAMIX	• *Generalized Myasthenia Gravis, US*
SPECIAL TOPIX	• *Biologic Coordinators in Generalized Myasthenia Gravis* • ***Ocular Myasthenia Gravis* +***

Duchenne Muscular Dystrophy

MARKET DYNAMIX	• ***Duchenne Muscular Dystrophy, US +***
LAUNCH DYNAMIX	• ***Deramiocel (Capricor Therapeutics) in Duchenne Muscular Dystrophy, US* +*** • ***Z-rostudirsen / DYNE-251 (Dyne Therapeutics) in Duchenne Muscular Dystrophy, US* +*** • ***SGT-003 (Solid Biosciences) in Duchenne Muscular Dystrophy, US* +*** • ***RGX-202 (REGENXBIO) in Duchenne Muscular Dystrophy, US* +***

Psychiatric Indications

MARKET DYNAMIX	• *Schizophrenia, US* • ***Major Depressive Disorder, US +*** • ***Bipolar Disorder, US +***
SPECIAL TOPIX	• *Behavioral and Psychiatric Symptoms in Alzheimer's Disease, US*

Key

MARKET DYNAMIX	*Yearly market overview of key indication*
REALTIME DYNAMIX	*Quarterly (US) or semi-annual (EU4 +UK) indication updates*
LAUNCH DYNAMIX	*Monthly benchmark of newly launched products*
PATIENT CHART DYNAMIX	*Yearly review of large-scale patient chart audits*
PATIENT VOICE DYNAMIX	*Independent service capturing patient journey insights*
SPECIAL TOPIX	*Current events on specific interest areas*
RAPIDPULSE DYNAMIX	*Rapid market intelligence for time-sensitive decisions*

**Pending approvals and launch*

+ New in 2027

Publications may change due to factors such as FDA approval status and other market events

2026 & 2027 Obesity Publications

MASH

MARKET DYNAMIX	• *MASH, US* • *MASH, EU4 +UK*
LAUNCH DYNAMIX	• *Rezdiffra (Madrigal) in MASH, US* • *Wegovy (Novo Nordisk) in MASH, US*
PATIENT CHART DYNAMIX	• ***MASH, US +***
SPECIAL TOPIX	• *MASH Screening and Management among PCPs and Endocrinologists, US*

CKD, Non-Dialysis

PATIENT CHART DYNAMIX	• *Chronic Kidney Disease, Non-Dialysis, Nephrologist, US* • *Chronic Kidney Disease, Non-Dialysis, PCP, US*
PATIENT VOICE DYNAMIX	• *Chronic Kidney Disease, US*

Obesity

MARKET DYNAMIX	• *Obesity, US*
LAUNCH DYNAMIX	• *Wegovy Pill (Novo Nordisk) in Obesity, US* • *Foundayo (Eli Lilly) in Obesity, US* • *CagriSema (Novo Nordisk) in Obesity, US** • ***Retatrutide (Eli Lilly) in Obesity, US* +***
PATIENT CHART DYNAMIX	• ***Obesity, US +***
PATIENT VOICE DYNAMIX	• ***Obesity, US +***

Key

MARKET DYNAMIX	*Yearly market overview of key indication*
REALTIME DYNAMIX	*Quarterly (US) or semi-annual (EU4 +UK) indication updates*
LAUNCH DYNAMIX	*Monthly benchmark of newly launched products*
PATIENT CHART DYNAMIX	*Yearly review of large-scale patient chart audits*
PATIENT VOICE DYNAMIX	*Independent service capturing patient journey insights*
SPECIAL TOPIX	*Current events on specific interest areas*
RAPIDPULSE DYNAMIX	*Rapid market intelligence for time-sensitive decisions*

**Pending approvals and launch*

+ ***New in 2027***

Publications may change due to factors such as FDA approval status and other market events

2026 & 2027 Oncology Publications

Hematologic Oncology

Acute Myeloid Leukemia

MARKET DYNAMIX	• *Acute Myeloid Leukemia, US*
LAUNCH DYNAMIX	• *Komzifti (Kura) in Acute Myeloid Leukemia, US* • *Revuforj (Syndax) in Acute Myeloid Leukemia, US*

B-Cell Malignancies

MARKET DYNAMIX	• *B-Cell Malignancies, US* • *Large B-Cell Lymphoma, EU*
PATIENT CHART DYNAMIX	• *Large B-Cell Lymphoma, US* • *Chronic Lymphocytic Leukemia, US*
PATIENT VOICE DYNAMIX	• *B-Cell Malignancies, US*

Multiple Myeloma

MARKET DYNAMIX	• *Multiple Myeloma, EU4 +UK*
REALTIME DYNAMIX	• *Multiple Myeloma, US*
LAUNCH DYNAMIX	• *Lynozyfic (Regeneron) in Multiple Myeloma, US* • *Blenrep (GSK) in Multiple Myeloma, US* • *Darzalex Faspro (J&J) in High-Risk Smoldering Multiple Myeloma, US* • ***Anito-cel (Gilead/Kite) in Multiple Myeloma, US*** [+] • ***Mezigdomide (Bristol Myers Squibb) in Multiple Myeloma, US*** [+]
PATIENT CHART DYNAMIX	• *Multiple Myeloma, US*
PATIENT VOICE DYNAMIX	• *Multiple Myeloma, US*
SPECIAL TOPIX	• *High-Risk Smoldering Multiple Myeloma, US*

Myeloproliferative Neoplasms (MPN)

MARKET DYNAMIX	• *Myeloproliferative Neoplasms, US*

Medical Oncology

Solid Tumors

REALTIME DYNAMIX	• *PD-1 Inhibition in Solid Tumors, US* • ***RAS-Driven Solid Tumors, US*** [+]

Other Oncology Indications

SPECIAL TOPIX	• *AI in Hematology and Oncology, US (2026)* • ***Cell Therapy in Solid Tumors, US*** [+] • ***Coordination between Community + Academic Physicians in Advanced Oncology, US*** [+] • ***Oncology Vaccines, US*** [+] • ***Oncologist Use of AI*** [+]

Key

MARKET DYNAMIX	*Yearly market overview of key indication*
REALTIME DYNAMIX	*Quarterly (US) or semi-annual (EU4 +UK) indication updates*
LAUNCH DYNAMIX	*Monthly benchmark of newly launched products*
PATIENT CHART DYNAMIX	*Yearly review of large-scale patient chart audits*
PATIENT VOICE DYNAMIX	*Independent service capturing patient journey insights*
SPECIAL TOPIX	*Current events on specific interest areas*
RAPIDPULSE DYNAMIX	*Rapid market intelligence for time-sensitive decisions*

**Pending approvals and launch*

[+] ***New in 2027***

Publications may change due to factors such as FDA approval status and other market events

2026 & 2027 Ophthalmology Publications

Diabetic Macular Edema & Neovascular Age-Related Macular Degeneration	
REALTIME DYNAMIX	• *Diabetic Macular Edema & Age-Related Macular Degeneration, US*
LAUNCH DYNAMIX	• ***Axpaxli (Ocular Therapeutix) in Neovascular Age-Related Macular Degeneration, US*** ⁺ • ***Zenkuda (Kodiak Sciences) in Neovascular Age-Related Macular Degeneration & Diabetic Retinopathy, US*** ⁺
PATIENT CHART DYNAMIX	• *Age-Related Macular Degeneration, US*

Other Ophthalmology Indications	
MARKET DYNAMIX	• *Diabetic Retinopathy, US* • ***Glaucoma, US*** ⁺ • ***Geographic Atrophy, US*** ⁺ • ***Thyroid Eye Disease (TED), US*** ⁺
LAUNCH DYNAMIX	• *Lumvoa, (Viridian) in Thyroid Eye Disease (TED), US* • ***Enspryng (Genentech) in Thyroid Eye Disease (TED), US*** ⁺
SPECIAL TOPIX	• *Gene Therapies in Retina, US* • ***Ophthalmologist Use of AI*** ⁺

Key

MARKET DYNAMIX	*Yearly market overview of key indication*
REALTIME DYNAMIX	*Quarterly (US) or semi-annual (EU4 +UK) indication updates*
LAUNCH DYNAMIX	*Monthly benchmark of newly launched products*
PATIENT CHART DYNAMIX	*Yearly review of large-scale patient chart audits*
PATIENT VOICE DYNAMIX	*Independent service capturing patient journey insights*
SPECIAL TOPIX	*Current events on specific interest areas*
RAPIDPULSE DYNAMIX	*Rapid market intelligence for time-sensitive decisions*

**Pending approvals and launch*

⁺ ***New in 2027***

Publications may change due to factors such as FDA approval status and other market events

2026 & 2027 Respiratory Publications

Asthma

MARKET DYNAMIX	• *Asthma, US* • *Asthma, EU*
PATIENT VOICE DYNAMIX	• ***Asthma, US*** [+]

Chronic Obstructive Pulmonary Disease

MARKET DYNAMIX	• *Chronic Obstructive Pulmonary Disease, US* • *Chronic Obstructive Pulmonary Disease, EU*
PATIENT VOICE DYNAMIX	• ***Chronic Obstructive Pulmonary Disease, US*** [+]

Interstitial Lung Disease

SPECIAL TOPIX	• *ILD in Rheumatology, US (2026)*

Key

MARKET DYNAMIX	*Yearly market overview of key indication*
REALTIME DYNAMIX	*Quarterly (US) or semi-annual (EU4 +UK) indication updates*
LAUNCH DYNAMIX	*Monthly benchmark of newly launched products*
PATIENT CHART DYNAMIX	*Yearly review of large-scale patient chart audits*
PATIENT VOICE DYNAMIX	*Independent service capturing patient journey insights*
SPECIAL TOPIX	*Current events on specific interest areas*
RAPIDPULSE DYNAMIX	*Rapid market intelligence for time-sensitive decisions*

**Pending approvals and launch*

[+] ***New in 2027***

Publications may change due to factors such as FDA approval status and other market events

2026 & 2027 Rheumatology Publications

Spondyloarthritis (AS, nr-AxSpA, and PsA)

MARKET DYNAMIX	• *Ankylosing Spondylitis & nr-AxSpA, US* ⁺ • *Ankylosing Spondylitis & nr-AxSpA, EU4 +UK (2025)* • *Psoriatic Arthritis, EU4 +UK (2025)*
REALTIME DYNAMIX	• *Psoriatic Arthritis, US*
LAUNCH DYNAMIX	• *Bimzelx (UCB) in AS & nr-AxSpA, US* • *Bimzelx (UCB) in Psoriatic Arthritis, US* • *Sotyktu (BMS) in Psoriatic Arthritis, US* • *Ilumya (Sun) in Psoriatic Arthritis, US*
PATIENT VOICE DYNAMIX	• *Psoriatic Arthritis, US*

Other Rheumatology Indications

MARKET DYNAMIX	• *Idiopathic Inflammatory Myopathies, US (2026 Refresh)* • ***IgG4-RD, US*** ⁺ • *Rheumatoid Arthritis, US (2026 Refresh)* • *Rheumatoid Arthritis, EU4 +UK (2025)* • *Sjogren's Disease, US (2026 Refresh)* • *Systemic Sclerosis, US*
LAUNCH DYNAMIX	• *Rinvoq (AbbVie) in Giant Cell Arteritis, US* • *Cosentyx (Novartis) in PMR, US** • *Lisraya (Priovant Therapeutics) in Dermatomyositis, US* • ***Ianalumab (Novartis) in Sjogren's Disease, US** ⁺* • ***Obexelimab (Zenas) in IgG4-RD, US** ⁺* • ***Vyvgart Hytrulo (argenx) in IIM, US** ⁺*
PATIENT VOICE DYNAMIX	• ***Sjogren's Disease, US*** ⁺ • ***Psoriatic Arthritis, US*** ⁺
SPECIAL TOPIX	• *Biologic Coordinators Across Rheumatology, US* • *Cell Therapy in Rheumatology, US* • *ILD in Rheumatology, US* • *Rheumatologists' Use of AI, US* • *Rheumatology Patient Use of AI, US* • ***Business of Rheumatology, US*** ⁺

Lupus

MARKET DYNAMIX	• *Cutaneous Lupus, US (2026)* • *Systemic Lupus Erythematosus, EU4 +UK* • ***Systemic Lupus Erythematosus, China*** ⁺ • *Lupus Nephritis, China* ⁺
REALTIME DYNAMIX	• *Systemic Lupus Erythematosus, US* • *Lupus Nephritis, US* • ***Systemic Lupus Erythematosus, EU4 +UK*** ⁺ • *Lupus Nephritis, EU4 +UK* • ***Systemic Lupus Erythematosus, Brazil*** ⁺ • *Lupus Nephritis, Brazil* • ***Systemic Lupus Erythematosus, Canada*** ⁺ • *Lupus Nephritis, Canada*
LAUNCH DYNAMIX	• *Gazyva (Genentech) in Lupus Nephritis, US* • *Saphnelo SC (AstraZeneca) in Systemic Lupus Erythematosus, US* • ***Gazyva (Genentech) in Systemic Lupus Erythematosus, US** ⁺ ⁺* • ***Litifilimab (Biogen) in Systemic Lupus Erythematosus, US** ⁺ ⁺* • ***Sotyktu (BMS) in Systemic Lupus Erythematosus, US** ⁺ ⁺* • ***Rinvoq (AbbVie) in Systemic Lupus Erythematosus, US** ⁺ ⁺*
PATIENT CHART DYNAMIX	• *Cutaneous Lupus, US* • *Lupus Nephritis, US* • *Systemic Lupus Erythematosus, US* • *Systemic Lupus Erythematosus & Lupus Nephritis, EU4 +UK*
PATIENT VOICE DYNAMIX	• *Systemic Lupus Erythematosus & Lupus Nephritis, US*

Key

MARKET DYNAMIX	*Yearly market overview of key indication*
REALTIME DYNAMIX	*Quarterly (US) or semi-annual (EU4 +UK) indication updates*
LAUNCH DYNAMIX	*Monthly benchmark of newly launched products*
PATIENT CHART DYNAMIX	*Yearly review of large-scale patient chart audits*
PATIENT VOICE DYNAMIX	*Independent service capturing patient journey insights*
SPECIAL TOPIX	*Current events on specific interest areas*
RAPIDPULSE DYNAMIX	*Rapid market intelligence for time-sensitive decisions*

**Pending approvals and launch*

⁺ ***New in 2027***

Publications may change due to factors such as FDA approval status and other market events

Visit The Spherix Portal



Looking for more?
Visit the Spherix Portal

The Spherix Portal helps clients interact with their data and insights so they can find answers to their important questions.

By using the portal, Spherix clients can access all their subscribed data and easily integrate intelligence into their research projects.

Access to the Spherix Portal is open to anyone. It's the best way to find the right product to fit your needs.

Create your free account at www.clientportal.spherixglobalinsights.com